Schroder Investment Management Group acquired a new stake in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 25,305 shares of the biotechnology company’s stock, valued at approximately $988,000. Schroder Investment Management Group owned about 0.09% of Five Prime Therapeutics at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in FPRX. Bank of America Corp DE raised its stake in Five Prime Therapeutics by 5.8% during the first quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock valued at $671,000 after buying an additional 1,025 shares during the last quarter. Rhumbline Advisers raised its stake in Five Prime Therapeutics by 1.4% during the second quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock valued at $1,032,000 after buying an additional 484 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in Five Prime Therapeutics during the second quarter valued at $602,000. Alps Advisors Inc. raised its stake in Five Prime Therapeutics by 6.1% during the second quarter. Alps Advisors Inc. now owns 25,966 shares of the biotechnology company’s stock valued at $782,000 after buying an additional 1,498 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Five Prime Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 228,350 shares of the biotechnology company’s stock worth $6,876,000 after purchasing an additional 4,474 shares during the last quarter. Institutional investors and hedge funds own 83.80% of the company’s stock.

Five Prime Therapeutics Inc (FPRX) opened at $20.05 on Friday. Five Prime Therapeutics Inc has a one year low of $19.73 and a one year high of $53.89.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business had revenue of $8.33 million during the quarter, compared to analysts’ expectations of $16.16 million. During the same quarter in the prior year, the firm earned ($0.72) EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. equities research analysts anticipate that Five Prime Therapeutics Inc will post -5.56 EPS for the current fiscal year.

In related news, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the sale, the director now owns 600 shares of the company’s stock, valued at $27,198. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $76,000. The disclosure for this sale can be found here. Insiders sold 4,400 shares of company stock valued at $175,666 in the last ninety days. 6.50% of the stock is currently owned by corporate insiders.

FPRX has been the subject of several recent analyst reports. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Jefferies Group restated a “buy” rating and issued a $52.00 price target on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Royal Bank of Canada initiated coverage on Five Prime Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price target for the company. BMO Capital Markets restated a “hold” rating and issued a $39.00 price target on shares of Five Prime Therapeutics in a research note on Friday, September 22nd. Finally, Zacks Investment Research cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Five Prime Therapeutics has an average rating of “Hold” and an average price target of $64.00.

ILLEGAL ACTIVITY NOTICE: “Schroder Investment Management Group Acquires Shares of 25,305 Five Prime Therapeutics Inc (FPRX)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/16/schroder-investment-management-group-acquires-shares-of-25305-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related stocks with our FREE daily email newsletter.